4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestive Disease Week (DDW) 2021

Rhea-AI Summary

4D pharma plc (NASDAQ: LBPS) announced it will present data from its Phase II study of Blautix® for irritable bowel syndrome (IBS) subtypes IBS-C and IBS-D at Digestive Disease Week (DDW) 2021 from May 21-23. The presentation will occur on May 22, 2021, led by Dr. Eamonn Quigley. A virtual event will follow on May 25, 2021, analyzing the data and current IBS treatments, featuring a management presentation and Q&A session. 4D pharma specializes in Live Biotherapeutics and has multiple clinical programs underway, targeting various diseases.

4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that it will present data from its Phase II study of single strain LBP Blautix® in patients with irritable bowel syndrome (IBS) subtypes IBS-C and IBS-D in a poster session at Digestive Disease Week (DDW) 2021, taking place virtually May 21-23, 2021.

Details of the poster presentation are as follows:

Presentation Title: A Phase II Study of Live Biotherapeutic Blautix in Irritable Bowel Syndrome (IBS) Patients with Subtypes IBS-C and IBS-D.
Session Date & Time: Saturday, May 22, 2021 from 12:15pm to 1:00pm EDT (5:15pm to 6:00pm BST)
Session Title: Microbial-Based Therapy
Presenter: Eamonn Quigley, M.D. Chief, Division of Gastroenterology and Hepatology at Houston Methodist
Abstract Number: 3525656

4D pharma will host a virtual event to review the additional data presented at DDW 2021 and how this relates to the current IBS treatment landscape. The event will take place on Tuesday, May 25, 2021 at 5:00pm BST (12:00pm EDT). The event will feature a presentation from 4D pharma management followed by an analyst Q&A session.

A live webcast of the event will be available via the Events section of the 4D pharma website at www.4dpharmaplc.com. To access the call, please dial +1-760-294-1674 (United States) or +44-203-059-58-69 (United Kingdom) and reference Conference ID 20210360. A replay of the webcast will be available following the event.

About 4D pharma

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005223/en/

FAQ

What is the focus of 4D pharma's presentation at DDW 2021?

4D pharma will present data on its Phase II study of Blautix® for IBS-C and IBS-D at Digestive Disease Week 2021.

When and where will 4D pharma's presentation take place?

The presentation is scheduled for May 22, 2021, at DDW 2021, which is being held virtually.

Who will present the data on Blautix® at DDW 2021?

Dr. Eamonn Quigley will present the data on Blautix® at the session.

What is the date and time of the virtual event hosted by 4D pharma?

The virtual event will take place on May 25, 2021, at 5:00 PM BST (12:00 PM EDT).

How can I access the webcast of 4D pharma's virtual event?

The webcast can be accessed through the Events section of the 4D pharma website.

What are the IBS subtypes being studied in the Phase II trial of Blautix®?

The Phase II trial focuses on irritable bowel syndrome subtypes IBS-C and IBS-D.

What is the significance of Live Biotherapeutics in 4D pharma's research?

Live Biotherapeutics represent a novel class of drugs that utilize live organisms for the prevention and treatment of diseases.